Orphan Incentives: Voucher Price Drop Gives Some Sponsors 'Pause'
Executive Summary
Is the lower sale price making the opportunity for a priority review voucher less an incentive for orphan development?
You may also be interested in...
Rare Pediatric Disease Priority Review Voucher Not Generating New Drug Trials
Researchers find no significant difference in number of rare pediatric disease treatments starting clinical development before or after incentive was created, but advocates aren't ready to give up on the program yet.
A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.
Priority Review Voucher Crash: Spark's Sale To Jazz Lowest Price Since 2014
Only the first publicly disclosed sale of a priority review voucher was lower than what Jazz Pharmaceuticals paid Spark Therapeutics for its coupon.